Cargando…
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Tremendous efforts have been made over the past few decades to discover novel cancer biomarkers for use in clinical practice. However, a striking discrepancy exists between the effort directed toward biomarker discovery and the number of markers that make it into clinical practice. One of the confou...
Autores principales: | Füzéry, Anna K, Levin, Joshua, Chan, Maria M, Chan, Daniel W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850675/ https://www.ncbi.nlm.nih.gov/pubmed/24088261 http://dx.doi.org/10.1186/1559-0275-10-13 |
Ejemplares similares
-
Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples
por: Petushkova, Natalia A., et al.
Publicado: (2017) -
The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021) -
Timelines of translational science: From technology initiation to FDA approval
por: McNamee, Laura M., et al.
Publicado: (2017) -
A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018) -
Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)